The GPC1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product provides a heterogeneous pool of cells with targeted disruption of the GPC1 gene, enabling loss-of-function studies in a genetically diverse cellular context. The polyclonal format avoids clonal bias and captures the spectrum of CRISPR-induced genetic variants, offering a robust model for probing GPC1-related biology without the limitations of single-cell-derived clones.
A-549 cells, isolated from a 58-year-old Caucasian male with lung carcinoma, serve as a widely used alveolar basal epithelial cell model in lung cancer research. These adherent epithelial cells retain key characteristics of type II pneumocytes and are proficient in forming monolayers suitable for signaling, migration, and invasion assays. Their well-characterized karyotype and growth properties make them a reliable platform for examining tumorigenic mechanisms and therapeutic interventions in non-small cell lung adenocarcinoma.
GPC1 encodes glypican-1, a cell surface heparan sulfate proteoglycan that acts as a co-receptor for heparin-binding growth factors such as FGF2 and VEGF. By promoting ligand?Creceptor complex formation, GPC1 enhances FGF/FGFR/ERK, Wnt/Frizzled/??-catenin, and TGF-??/Smad signaling cascades. In A-549 cells, GPC1 is regulated by SP1 and responds to Wnt, FGF, and TGF-?? ligands, leading to transcriptional activation of cyclin D1, c-Myc, and ??-catenin/TCF targets. Knockout of GPC1 disrupts these mitogenic and migratory signals, attenuating proliferation and adhesion.
In lung adenocarcinoma cells, GPC1 is frequently overexpressed and contributes to enhanced growth factor responsiveness and metastatic potential. Disruption of GPC1 in A-549 cells creates a valuable model for dissecting its role in sustaining oncogenic signaling networks, particularly those mediated by FGF2, VEGF, and ??-catenin. This knockout system enables researchers to interrogate how heparan sulfate proteoglycans modulate ligand bioavailability, receptor activation kinetics, and crosstalk between parallel pathways, offering insights into tumor cell proliferation, epithelial-mesenchymal transition, and matrix remodeling.
Typical experimental applications include comparing phospho-ERK, phospho-Smad, and active ??-catenin levels by western blotting or flow cytometry, quantifying transcript changes of cyclin D1 and c-Myc via RT-qPCR, and assessing cell migration and invasion using transwell assays. The polyclonal pool is particularly suited for drug target validation screens and tumor microenvironment co-culture studies where heterogeneous genetic perturbation better recapitulates tumor heterogeneity. For additional technical specifications, lot-specific quality control data, or assistance with experimental design, please contact Ascent Research.
